Robert Foster, Hepion Pharmaceuticals CEO

As it awaits key read­out, He­p­i­on boosts con­fi­dence in NASH drug hope­ful via short­er study

He­p­i­on Phar­ma­ceu­ti­cals said Mon­day morn­ing its drug for non­al­co­holic steato­hep­ati­tis, or NASH, im­proved liv­er func­tion ac­cord­ing to an ex­per­i­men­tal di­ag­nos­tic and al­so im­proved key bio­mark­ers as­so­ci­at­ed with the dis­ease.

In a Phase II study, the New Jer­sey biotech used an in­ves­ti­ga­tion­al test from col­lab­o­ra­tor Hep­Quant, a liv­er di­ag­nos­tics com­pa­ny in Den­ver, to ex­am­ine liv­er func­tion and im­pair­ment in over 60 pa­tients be­fore and af­ter they re­ceived He­p­i­on’s drug can­di­date ren­cofil­stat. He­p­i­on used the test to mea­sure a num­ber of items in­clud­ing dis­ease sever­i­ty, which was the pri­ma­ry end­point of the study.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Alexandria Real Estate Equities

Cambridge, MA, USA